Cargando…
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of antidiabetes drugs, and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus (T2DM). It is widely accepted that SGLT2 is responsible for >80% of the reabsorpt...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781482/ https://www.ncbi.nlm.nih.gov/pubmed/24065789 http://dx.doi.org/10.2337/db13-0604 |
_version_ | 1782285428269776896 |
---|---|
author | Abdul-Ghani, Muhammad A. DeFronzo, Ralph A. Norton, Luke |
author_facet | Abdul-Ghani, Muhammad A. DeFronzo, Ralph A. Norton, Luke |
author_sort | Abdul-Ghani, Muhammad A. |
collection | PubMed |
description | Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of antidiabetes drugs, and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus (T2DM). It is widely accepted that SGLT2 is responsible for >80% of the reabsorption of the renal filtered glucose load. However, maximal doses of SGLT2 inhibitors fail to inhibit >50% of the filtered glucose load. Because the clinical efficacy of this group of drugs is entirely dependent on the amount of glucosuria produced, it is important to understand why SGLT2 inhibitors inhibit <50% of the filtered glucose load. In this Perspective, we provide a novel hypothesis that explains this apparent puzzle and discuss some of the clinical implications inherent in this hypothesis. |
format | Online Article Text |
id | pubmed-3781482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-37814822014-10-01 Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans Abdul-Ghani, Muhammad A. DeFronzo, Ralph A. Norton, Luke Diabetes Perspectives in Diabetes Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of antidiabetes drugs, and members of this class are under various stages of clinical development for the management of type 2 diabetes mellitus (T2DM). It is widely accepted that SGLT2 is responsible for >80% of the reabsorption of the renal filtered glucose load. However, maximal doses of SGLT2 inhibitors fail to inhibit >50% of the filtered glucose load. Because the clinical efficacy of this group of drugs is entirely dependent on the amount of glucosuria produced, it is important to understand why SGLT2 inhibitors inhibit <50% of the filtered glucose load. In this Perspective, we provide a novel hypothesis that explains this apparent puzzle and discuss some of the clinical implications inherent in this hypothesis. American Diabetes Association 2013-10 2013-09-17 /pmc/articles/PMC3781482/ /pubmed/24065789 http://dx.doi.org/10.2337/db13-0604 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Perspectives in Diabetes Abdul-Ghani, Muhammad A. DeFronzo, Ralph A. Norton, Luke Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title | Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title_full | Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title_fullStr | Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title_full_unstemmed | Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title_short | Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans |
title_sort | novel hypothesis to explain why sglt2 inhibitors inhibit only 30–50% of filtered glucose load in humans |
topic | Perspectives in Diabetes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781482/ https://www.ncbi.nlm.nih.gov/pubmed/24065789 http://dx.doi.org/10.2337/db13-0604 |
work_keys_str_mv | AT abdulghanimuhammada novelhypothesistoexplainwhysglt2inhibitorsinhibitonly3050offilteredglucoseloadinhumans AT defronzoralpha novelhypothesistoexplainwhysglt2inhibitorsinhibitonly3050offilteredglucoseloadinhumans AT nortonluke novelhypothesistoexplainwhysglt2inhibitorsinhibitonly3050offilteredglucoseloadinhumans |